SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company
SL Science highlights regulatory, preclinical and manufacturing progress on its γδ T cell platform as it caps its first quarter on Nasdaq.
Rhea-AI Summary
SL Science Holding Limited (SLBT) rang the Nasdaq opening bell at MarketSite in New York to mark its first quarter as a publicly traded company, following its June 15, 2026 listing after a business combination with Horizon Space Acquisition II Corp.
During this eleven-week period, the company advanced its γδ T cell platform, highlighted by an ongoing Orphan Drug Designation request for Vdelta2+ γδT cells in glioblastoma multiforme under FDA review since March 2026, for which additional nonclinical data are being prepared. Preclinical intracranial γδT cell therapy data in glioblastoma models were exhibited in July 2026 at the World Congress of Basic and Clinical Pharmacology. SL Science licenses its γδT cell platform from JY BioMed for brain and pancreatic cancers and has filed FDA Drug Master Files covering γδT cells and γδT-derived exosomes to support Chemistry, Manufacturing, and Controls for future commercialization.
Positive
- Orphan Drug Designation request for Vdelta2+ γδT cells in glioblastoma multiforme has been under FDA review since March 2026, with additional nonclinical data in preparation.
- Preclinical γδT cell therapy data in glioblastoma models were exhibited in July 2026 at the World Congress of Basic and Clinical Pharmacology.
- Drug Master Files for γδT cells and γδT-derived exosomes are filed with the FDA, establishing a CMC foundation for both product formats.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 27 | Regulatory update | Positive | +1.5% | FDA Drug Master File for exosomes extended platform manufacturing documentation across cellular and cell-free formats. |
| Aug 11 | Clinical publication | Positive | -5.7% | Peer-reviewed framework outlined future clinical-development standards for glioblastoma γδ T-cell therapy. |
| Jul 17 | Preclinical research | Positive | -0.7% | Preclinical glioblastoma research was exhibited at an international pharmacology congress. |
| Jul 10 | Regulatory request | Positive | +3.7% | FDA acknowledged the Orphan Drug Designation request and reviewed additional files. |
| Jun 18 | Earnings report | Negative | -21.9% | Full-year results showed lower revenue, a net loss, and reduced cash. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive scientific and regulatory updates produced mixed reactions, while the financial-results release aligned with a sharp decline.
Key Terms
orphan drug designation regulatory
drug master files regulatory
chemistry, manufacturing, and controls regulatory
major histocompatibility complex medical
checkpoint inhibitors medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that its management team rang Nasdaq bell at the Nasdaq MarketSite in Times Square, New York, to celebrate its first quarter as a publicly traded company.
The ceremony marked the Company’s first appearance at Nasdaq since completing its business combination with Horizon Space Acquisition II Corp. and commencing trading under the ticker symbol “SLBT” on June 15, 2026. It also closes out SL Science's first quarter as a public company, a period during which the Company advanced its Gamma Delta (γδ) T cell platform across scientific, academic, and regulatory fronts.
From Listing to Execution: Progress Since June 15, 2026
SL Science reached key strategic milestones this quarter to support its clinical development trajectory, led by its ongoing Orphan Drug Designation (ODD) request for Vdelta2+ γδT cells in glioblastoma multiforme (DRU-2026-11528) under the U.S. Food and Drug Administration (FDA) review since March 2026, with the Company currently preparing additional nonclinical data requested by the agency.
Building on this regulatory momentum, preclinical research jointly conducted with research partners on intracranial γδT cell therapy in glioblastoma models was exhibited in July 2026 at the World Congress of Basic and Clinical Pharmacology in Melbourne, Australia.
These advancements are powered by SL Science’s γδT cell platform, licensed from IP holder JY BioMed for brain and pancreatic cancer indications. Operating independently of major histocompatibility complex (MHC) presentation, γδT cells directly engage tumor cells to bypass immune evasion and tumor heterogeneity, offering a scalable cell population that complements modalities like mRNA therapies and checkpoint inhibitors.
To support commercialization, Drug Master Files (DMFs) covering both γδT cells and γδT-derived exosomes are filed with the FDA, providing confidential quality and manufacturing data that establish a documented Chemistry, Manufacturing, and Controls (CMC) foundation across both product formats.
Management Commentary
“Ringing the bell at Nasdaq is a moment worth marking, but what matters is what we have done with the eleven weeks since we started trading,” said Mr. William Wang, Chairman and Chief Executive Officer of SL Science.“We have continued to advance our scientific and development efforts while building the foundation for the next stage of growth. We believe the future of cancer treatment will increasingly involve complementary approaches. γδ T cells have the potential to play an important role alongside advances such as mRNA-based cancer vaccines and checkpoint inhibitors. We believe these approaches have the potential to open new possibilities in cancer treatment. Standing here at Nasdaq today is a marker on that path, not the destination.”
About SL Science Holding Limited
SL Science Holding Limited is a biomedical company specializing in developing innovative cellular and gene therapies. Established with a commitment to advancing regenerative medicine and cancer treatment, the Company hopes to utilize immune cell technologies to target cancer, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Gamma Delta T cells targeting solid tumor indications including pancreatic and brain cancers, SL Science aims to create cellular therapies that we believe have the potential to revolutionize the cell therapy and immuno-oncology sector within the broader biopharmaceutical industry. For more information, please visit the Company's website at: https://www.slbtgroup.com/ and follow SLBT on X, LinkedIn, FB, IG and Threads.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the business of SL Science. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: the ability to successfully implement the Company's business plans and clinical trials; the ability to obtain and maintain necessary regulatory approvals for its product candidates, including the outcome of the Company's Orphan Drug Designation request; the potential for its regenerative medicine products to reach commercialization; and the ability to recognize the anticipated benefits of the business combination. The Company assumes no obligation to update these forward-looking statements, except as required by applicable law.
Contact Details:
SL Science Holding Limited
Tel: +886-2-26516826
Email: ir@slbtgroup.com
WFS Investor Relations Inc.
Email: services@wfsir.com
+1 628 283 9214
